The following full text is a publisher’s version.

For additional information about this publication click this link. http://hdl.handle.net/2066/124865

Please be advised that this information was generated on 2017-11-19 and may be subject to change.
ORIGINAL ARTICLE

GATAD2B loss-of-function mutations cause a recognisable syndrome with intellectual disability and are associated with learning deficits and synaptic undergrowth in Drosophila

Marjolein H Willemsen,1 Bonnie Nijhof,1,2,3 Michaela Fenckova,1,2,3 Willy M Nillesen,1 Ernie M H F Bongers,1 Anna Castells-Nobau,1,2,3 Lenke Asztalos,4 Erika Viragh,5 Bregje W M van Bon,1 Emre Tezel,1,2,3 Joris A Veltman,1,2,6 Han G Brunner,1,6 Bert B A de Vries,1,6 Joep de Ligt,1,2,6 Helger G Yntema,1 Hans van Bokhoven,1,2,3 Bertrand Isidor,7 Cédric Le Caignec,7 Elsa Lorino,8 Zoltan Asztalos,4,5,9 David A Koolen,1 Lisena E L M Vissers,1,2,6 Annette Schenck,1,2,3 Tjitske Kleefstra1,3,6

ABSTRACT

Background GATA zinc finger domain containing 28 (GATAD2B) encodes a subunit of the MeCP1-Mi-2/nucleosome remodelling and deacetylase complex involved in chromatin modification and regulation of transcription. We recently identified two de novo loss-of-function mutations in GATAD2B by whole exome sequencing in two unrelated individuals with severe intellectual disability.

Methods To identify additional individuals with GATAD2B aberrations, we searched for microdeletions overlapping with GATAD2B in inhouse and international databases, and performed targeted Sanger sequencing of the GATAD2B locus in a selected cohort of 80 individuals based on an overlap with the clinical features in the two index cases. To address whether GATAD2B is required directly in neurones for cognition and neuronal development, we investigated the role of Drosophila GATAD2B orthologue simjang (simj) in learning and synaptic connectivity.

Results We identified a third individual with a 240 kb microdeletion encompassing GATAD2B and a fourth unrelated individual with GATAD2B loss-of-function mutation. Detailed clinical description showed that all four individuals with a GATAD2B aberration had a distinctive phenotype with childhood hypotonia, severe intellectual disability, limited speech, tubular shaped nose with broad nasal tip, short philtrum, sparse hair and strabismus. Neuronal knockdown of Drosophila GATAD2B orthologue, simj, resulted in impaired learning and altered synaptic morphology.

Conclusions We hereby define a novel clinically recognisable intellectual disability syndrome caused by loss-of-function of GATAD2B. Our results in Drosophila suggest that GATAD2B is required directly in neurones for normal cognitive performance and synaptic development.

INTRODUCTION

Intellectual disability (ID) is a group of disorders with an extremely heterogeneous clinical and genetic presentation. More than 500 ID genes have been identified and many more await discovery. This large number of ID genes is believed to converge onto a limited number of common underlying pathways and processes.1 Several ID genes encode proteins that are involved in chromatin modification.1,2

Since the recent advent of next generation sequencing technology, whole exome sequencing (WES) has been successfully applied to the identification of genes for clinically established ID syndromes.3–6 In addition, family based WES was successful in elucidating causative de novo gene mutations in sporadic individuals who do not present with a recognizable syndrome.7–9 However, exploration of the pathogenicity of mutations in genes not previously associated with ID remains challenging. To establish a conclusive molecular diagnosis, it is therefore required to detect mutations in the same candidate genes in additional individuals with similar phenotype.10 Moreover, additional evidence and insights into functional properties of novel genes are desirable and can be obtained through studies in cell or animal models.

By application of trio based WES, we recently reported the identification of 22 candidate genes for ID.8 Among these was the GATA zinc finger domain containing 2B (GATAD2B) gene (NM_020699.2). In this gene, we identified two loss-of-function mutations in two unrelated individuals (c.584dupT; p.(Asn195Ile) and c.1408 C>T; p.(Gln470*)). GATAD2B encodes p66beta, a subunit of the transcription repressor complex MeCP1-Mi-2/nucleosome remodelling and deacetylase (NuRD), responsible for silencing of methylated DNA by nucleosome remodelling and histone deacetylation.11,12

Here, we report an additional individual with a disruptive GATAD2B mutation (c.565_566del; p.(Gln190fs)), representing the third loss-of-function mutation in this gene. The mutation was revealed by direct Sanger sequencing in a selected cohort of 80 individuals with overlapping features comprising ID, childhood hypotonia and an abnormal shape of the nose (including a tubular shape, prominent and

broad base of the nose). In addition, we found a fourth individual with a 240 kb de novo microdeletion encompassing GATAD2B. Comparison of the phenotype of all four individuals revealed a remarkable overlap in clinical presentation.

Modelling of the Drosophila orthologue of GATAD2B loss-of-function confirms its role in cognition and shows a critical role of GATAD2B in synapse development. Together, our data establish a novel ID syndrome. It adds to the growing list of ID conditions that are caused by mutated genes involved in chromatin remodelling that can shed light onto the epigenetic control of cognition.

**METHODS**

**Patients**

Individuals 1 and 2 were ascertained through family based WES studies recently reported by our group7 8 (trio 4 in Vissers et al7 and trio 69 in Lagt et al8 respectively). The GATAD2B mutation in individual 1 was noticed in retrospect upon reanalysis of the sequencing data, after the detection of the mutation in individual 2.

Subsequently, we searched for individuals with small microdeletions overlapping with GATAD2B in our inhouse database and international databases, including the database of the European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations (ECARUCA) and the Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources (Decipher).

In addition, we selected a cohort of 80 individuals guided by phenotypic overlap with individuals 1 and 2. This cohort was selected based on the presence of severe ID (IQ ≤ 50), limited speech ability, childhood hypotonia and facial features including abnormal shaped nose (large/prominent nose, full nose tip, tubular shaped/pear-shaped nose, broad base of the nose). All individuals had been referred to the Department of Human Genetics of the Radboud University Medical Centre in Nijmegen, the Netherlands, for genetic diagnostic evaluation of unexplained ID/developmental delay. Their parents/legal representatives consented to this study. The study was approved by the local ethical committee.

**Mutation screening**

Targeted Sanger sequencing of GATAD2B (NM_020699.2) was performed using standardised methods. Primers are available upon request. The mutation in individual 4 and the low grade mosaic in her mother were confirmed with a second independent primer pair.

**Fly stocks and maintenance**

Fly stocks were kept on standard Drosophila diet (cornmeal/sugar/yeast) at 25°C and 45%-60% humidity at 12 h light–dark cycle. Flies were reared at 25°C, 70% humidity for habituation experiments and real-time PCR, and at 28°C, 60% humidity to evaluate synapse morphology. Simjiang (Simj) (CG32067) is the Drosophila orthologue of GATAD2B (Ensemble, see also Results section). An inducible RNA interference (RNAi) line against the Drosophila orthologue of GATAD2B, elav-Gal4 was expressed in the central nervous system (CNS) of flies (vdrc.at). RNAi was induced by the UAS-Gal4 system using a UAS-Dicer2 driver to gener-ate homogeneous knockdown material for real-time PCR.

**Drosophila synapse morphology**

Type 1b neuromuscular junctions (NMJs) at muscle 4 were analysed after dissection of L3 larvae and fixation in 3.7% paraformaldehyde (PFA) for 30 min. Preparations were colabelled for bruchpilot (brp) and discs large 1 (dlg1). Brp was visualised using the primary antibody ncd82 (1:125) (Developmental Studies Hybridoma Bank, University of Iowa) applied overnight at 4°C, and a secondary Alexa 488-labelled goat-antimouse antibody (1:500) (Invitrogen). Discs large was visualised using the primary antibody anti-dlg1 (1:25) (Developmental Studies Hybridoma Bank) in combination with the Zenon Alexa Fluor 568 Mouse IgG1 labelling kit (Invitrogen). NMJ pictures were obtained using a Leica automated brightfield multi-colour epi-fluorescent microscope. Individual synapses were imaged and the muscle area, NMJ area, perimeter, length, branching pattern and amount of active zones were quantitatively assessed using an inhouse developed macro.

**Analysis of simj mRNA levels by real-time PCR**

Total RNA from 3rd instar larval was isolated using RNAeasy Lipid Tissue Mini Kit (Qiagen). RNA was treated with DNase (DNasefree Kit, Ambion). First strand cDNA synthesis was performed using the Moloney Murine Leukemia Virus (M-MLV) Reverse Transcriptase (Life Technologies) and oligo(dT) primer. Gene expression was analysed by real-time PCR (7900HT Fast Real-Time PCR system, Applied Biosystems). PCR reactions were performed in a volume of 25 μl containing 150 nM primers and GoTag Green Mastermix (Promega). Primer sequences used for amplification of simj were 5'-CAGCACCATTCGTTGTG-3' (forward primer) and 3'-GGCTTAGTGTTCTTCC-3' (reverse primer). A PolII primer sequences were 5'-TAGAGCAGTCCGGGAA CACC-3' (forward primer) and 5'-TGTCACAAGTGGCTTCA TC-3' (reverse primer).
RESULTS
Clinical phenotype description
We here report the detailed clinical description of four affected individuals. Individual 1 (figure 1A–D) was born after 36 weeks and 5 days of pregnancy with a normal birth weight and no major complications upon delivery. At 2 years of age, her parents consulted a paediatrician because of global developmental delay. She could sit and crawl at the age of 16 months and stand at the age of 18 months. Hypotonia was noticed. After the age of 2 years she spoke her first words. An ophthalmologist was consulted because of strabismus. At the age of 3 years and 8 months she was able to speak about 30 single words, but her comprehension of language was at a higher level. She had a normal height (100 cm, 30th centile) and head circumference (47.5 cm, 10th centile). Her facial features included thin blond hair, narrow palpebral fissures, periorbital fullness, a tubular shape of the nose with full nasal tip, a short philtrum, thin upper lip, broad mouth and grimacing facial expression. Three years later, at the age of 6 years and 7 months she had severe developmental delay with verbal skills more severely impaired than motor skills. Her height was normal (118.5 cm, 16th centile) and she had a low to normal head circumference (48 cm, 2nd centile). Long fingers and toes with broad distal phalanges were observed.

Individual 2 (figure 1E–H) was born with intrauterine growth retardation. Her birth weight was 2780 g at 42 weeks of pregnancy (<2nd centile). At 3 months of age a developmental delay was noticed. She could walk independently at the age of 3 years. From 8 years on, she could speak single words. Behaviour was characterised by tics and wandering during the night. Her pain threshold was elevated. Vision was impaired due to hypoplasia of the optic nerve. Upon clinical evaluation at the age of 34 years she was diagnosed with severe ID. At that time, height and head circumference were normal (both >16th centile). She had thin blond hair, deeply set eyes, narrow and upward slanting palpebral fissures, strabismus, a tubular shape of the nose with broad nasal tip, and a large mouth with short philtrum and thin upper lip. She grimaced. Her fingers were long, thin and slightly tapering.

Individual 3 (figure 1I,J) was born after an uncomplicated pregnancy of 40 weeks duration, with a low-normal birth weight.
and a normal head circumference. In the neonatal period she presented with hypotonia and feeding difficulties. Her psychomotor development was delayed. She learnt to walk without support at the age of 2 years and 9 months. At the age of 3 years speech was severely delayed with only two to three disyllabic words. Her behaviour was characterised by low frustration tolerance. Medical problems included hypermetropia and strabismus and she had shown one episode of absence epilepsy. At the age of 3 years she had a height of 90 cm (5th centile), and a head circumference of 51 cm (84th centile). Facial dysmorphism included hypertelorism, a broad forehead, a broad and flat nasal bridge and a full square tip of the nose. She had thin, blond hair.

Individual 4 (figure 1K–N) was born after 42 weeks of pregnancy with a normal birth weight. Birth was uncomplicated. She was hypotonic and passive in the neonatal period. From the beginning on, psychomotor development was delayed with poor contact making. She learned to walk from the age of 2 years and started to speak during her third year. Her speech slowly developed, and at the age of 12 years she could only speak six single words. Her behaviour was characterised by hyperactivity, inappropriate laughter, obsession for shiny and reflecting objects and mild self-mutilation. Melatonin treatment was given for sleep problems. Medical problems included intermittent divergent strabismus and hypermetropic astigmatism, and persistent constipation. Around the age of 2–3 years absence epilepsy was suspected, but electroencephalography revealed no abnormalities. Upon physical examination at the age of 12 years and 2 months she had a height of 156 cm (50th centile), a weight of 43 kg (16th–50th centile) and a head circumference of 56.2 cm (80th–90th centile). Facial dysmorphism included hypertelorism, a broad forehead, a broad nasal bridge with full nose tip, a broad mouth with wide-spaced central incisors, short philtrum and long palpebral fissures. She had thin, blond hair. Her fingers were long and she had fleshy hands.

**Mutation detection**

Individual 1 showed no abnormalities on 250K Singly Nucleotide Polymorphism (SNP) array analysis, screening for Fragile X syndrome, a metabolic screen in blood and urine, and MRI imaging of the brain. Family based WES revealed a de novo frameshift mutation in GATAD2B (c.584dup; p. (Asn195fs); figure 2A). This mutation is located in the central part of the gene close to the conserved region 1 (CR1) domain (figure 2D). Likewise, individual 2 did not show any abnormality on 250K SNP array analysis and a metabolic screen. Methylation tests of the Angelman syndrome related region were normal. Family based exome sequencing revealed a de novo mutation in GATAD2B (c.1408 C>T; p.(Gln470*); figure 2B). This mutation is located in the conserved region 2 (CR2) domain (figure 2D).

![Figure 2](https://example.com/figure2.png)
Individual 4 was previously investigated for mutations in the genes FMR1, MECP2, TCF4, RA11 and UBE3A, all showing normal results. Methylation tests of the Angelman syndrome related region and a metabolic screen gave also normal results. Conventional G-band karyotyping yielded a maternally-inherited apparently balanced translocation between chromosomes 1q21.3 and 9q13. Further 250K SNP array analysis did not show any imbalances of these regions. Targeted sequencing of GATAD2B based on phenotypic overlap with the first two individuals led to the identification of a frameshift mutation (c.565_566del; p.(Gln190fs); figure 2C). This mutation is located at the border of the CR1 domain (2xGMR-wIR/+; elav-Gal4, UAS-Dicer2/+, black circles). Jump response was induced by repeated light-off pulses for 100 trials with 1 s inter-trial intervals and scored for a jump response. Flies were considered to have habituated once they failed to jump in five consecutive trials (no-jump criterion). Habituation was scored as the number of trials required to reach the no-jump criterion (TTC). Both genotypes showed wt-like initial jump responses. Control flies quickly habituated to the light-off stimuli and reduced jumping. We found that simj-RNAi flies habituate slower and maintain a higher jump response throughout the entire course of the experiment (figure 3A). The mean TTC of simj-RNAi flies was 1.7-fold higher compared with their genetic background controls (figure 3B, p=0.007), validating a significant deficit in habituation.

**GATAD2B is required for synaptic development in Drosophila**

Synaptic connectivity is essential for learning and for other cognitive processes. We therefore addressed a possible function of simj in synaptic development of the larval NMJ, a well-established synaptic model system that shares major features with central excitatory synapses in the mammalian brain and has been successfully used to investigate human ID disorders.

As in our habituation experiment, we investigated the Drosophila NMJ architecture upon panneuronal knockdown of simj. The synaptic and subsynaptic organisation was visualised by coimmunolabelling against dlg1 (α-dlg1), a major scaffolding component of larval NMJs and member of the membrane-associated guanylate kinase subfamily, and anti-brp (α-brp, nc82), an integral part of active zones.

Neurone-specific simj knockdown resulted in an NMJ undergrowth phenotype (figure 4A,B), with a consistent decrease in synaptic area (p=0.0028), perimeter (p=9.5e−03) and length.
New disease loci

Figure 4 Synapse morphology of neuromuscular junctions (NMJs) was studied in Simjang (simj) knockdown flies (UAS-simjRNAi100285/UAS-Dicer2; elav-Gal4/+ (A). NMJs were visualised with coimmunolabelling against discs large 1 (A, upper panel) and brp (A, middle panel) and quantitatively assessed by computer-assisted analysis (A, lower panel and B). Simj-RNA interference (RNAi) NMJs show a decrease in NMJ area (n=27, p=0.0028), perimeter (n=27, p=9.5e−005), length (n=28, p=5.7e−008), the amount of branches (n=28, p=0.041) and branching points (n=28, p=0.021) and the amount of active zones (n=25, p=0.0010). The area of the muscle remained normal (n=28, p=0.077). For this plot, red bars represent the mean of each parameter of Simj-RNAi NMJs normalised by the mean of each parameter of the control set (black bars). Error bars indicate the normalised standard error of the mean, p, p values (two-sided t test); n, number of quantified NMJs. (*) indicates a significant difference (p<0.05), (**) indicates a significant difference (p<0.01), (***)) indicates a significant difference (p<0.001). Access the article online to view this figure in colour.

Simj-RNAi synapses also exhibited a lower number of branches (p=0.041) and branching points (p=0.021). Last, simj-RNAi synapses showed a lower number of active zones (p=0.001), revealing a reduced number of pre-synaptic sites for neurotransmitter release. Muscle size was not affected, which excludes a general growth/developmental problem. We validated the potency of the used RNAi line to induce simj knockdown by real-time PCR. The level of simj mRNA was efficiently downregulated to 29% upon induction by a ubiquitous actin-Gal4 driver (p=0.0024; two-tailed t test). We validated the potency of the used RNAi line to induce simj knockdown by real-time PCR. The level of simj mRNA was efficiently downregulated to 29% upon induction by a ubiquitous actin-Gal4 driver (p=0.0024; two-tailed t test). We conclude that reduced levels of the GATAD2B orthologue simj affect synaptic development.

DISCUSSION

In this study, we report a novel clinically recognisable syndrome characterised by severe ID, limited speech, childhood hypotonia, thin hair and recognisable facial features, including a typical, tubular shaped nose with broad tip, deeply set eyes, broad forehead, short philtrum, broad mouth, grimacing facial expression, strabismus and long fingers caused by haploinsufficiency of GATAD2B. We recently identified by family based exome sequencing disruptive GATAD2B mutations in two individuals with overlapping phenotype. We traced a third individual with overlapping phenotype. We recently identified by family based exome sequencing disruptive GATAD2B mutations in two individuals with overlapping phenotype. We traced a third individual with overlapping phenotype. We recently identified by family based exome sequencing disruptive GATAD2B mutations in two individuals with overlapping phenotype. We traced a third individual with overlapping phenotype.

We therefore performed additional FISH analysis with the region 1q23.1 specific probe RP11-216N14 that covers the GATAD2B gene. This showed in all 29 evaluated cells a normal pattern, indicating that the translocation breakpoint is located distally from the GATAD2B region. Therefore, we concluded that this does not support a correlation between the mutation in GATAD2B and the balanced translocation.

Complementary functional studies of the Drosophila GATAD2B orthologue simj demonstrated a role for the evolutionarily conserved GATAD2B gene family in neurodevelopmental processes. The identified habituation defect in simj-RNAi flies demonstrates that the GATAD2B orthologue is required for non-associative learning. Furthermore, evaluation of synaptic morphology revealed an NMJ undergrowth phenotype with reduced number of active zones, suggesting a critical role for simj and GATAD2B in synaptic growth and function. Whether these may contribute to or cause the observed learning defects in flies and cognitive deficit in the humans remains to be determined.

Mutations in several recently identified genes involved in chromatin modification give rise to ID syndromes, such as the 17q21.31 microdeletion/Koolen-De Vries syndrome (KDVS (MIM 610443)), 23 24 Coffin-Siris syndrome13 25 (CSS (MIM135900)), Nicolaides-Baraitser syndrome26 27 (NCBRS (MIM 601358)), Kleefstra syndrome28 (MIM 610253), Wiedemann-Steiner syndrome29 (WDSTS (MIM 605130)) and Ohdo syndrome Say-Barber-Biesecker variant30 (SBBYSS (MIM 603736)).

GATAD2B encodes p66beta, which is a subunit of the transcription repressor complex MeCP1-Mi2-NuRD that silences methylated DNA by nucleosome remodelling and histone deacetylation. This enzyme complex also comprises its close paralogue p66alpha (encoded by GATAD2A), the histone deacetylases HDAC1 and HDAC2, two histone binding proteins RhAp46 and RhAp48, the methyl binding domain protein 3 (MBD3), two histone modifier proteins, MTA1 and MTA2, and nucleosome remodelling factor Mi-2.11 It is thus conceivable that additional genes from the MeCP1-Mi2-NuRD complex, such as GATAD2A, are involved in phenotypes overlapping with the here defined novel syndrome caused by GATAD2B mutations. P66beta and its parologue, p66alpha, function synergistically and recruit the Mi-2–NuRD complex to its target sites. They interact with methyl-CpG bound MBD2 and with
non-acetylated histones to assemble in the so-called MeCP1 repressor complex.11 It has been shown that p66alpha and p66beta, and particularly their highly conserved CR1 and CR2 domains, are crucial for complex formation and mediated gene silencing.12 Furthermore, homologous loss-of-function of p66alpha in mice resulted in an embryonic lethal phenotype with severe global malformations, growth retardation and necrosis. Heterozygous mice were viable and appeared normal, but detailed (neurological) phenotyping was not performed.3,11

We recently used the powerful strategy of combining human genetic studies and Drosophila modelling to provide a novel chromatin remodelling module that underlies Kleefer syndrome spectrum.7 Similar to that, we find a strikingly high conservation between human and Drosophila NuRD complexes, with all complex components being present in fly.3,12 As additional variants in human NuRD complex genes will arise, it will be straightforward to validate their significance. Our data add GATA2B, and possibly the whole MeCP1-Mi2–NuRD complex, to the growing list of ID genes involved in chromatin remodelling.

Author affiliations
1Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands
2Nijmegen Center for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands
3Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands
4Department of Genetics, Akkington, University of Cambridge, Cambridge, UK
5Institute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary
6Service for Genetic and Metabolic Disease, Radboud University Medical Centre, Nijmegen, The Netherlands
7Service de Pédiatrie, CHU Nantes, Nantes, France
8Service de Génétique Médicale, CHU Nantes, Nantes, France
9Institute for Genetic and Metabolic Disease, Radboud University Medical Centre, Nijmegen, The Netherlands
10Agriculture Hungary Ltd., Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary

Acknowledgements
We thank the participating individuals and their families. We also thank Suzanne Vetel-Keijzer and Martine Ruiterkamp for their technical assistance with the targeted Sanger sequencing.

Contributors
The study was designed and the results were interpreted by MHW, TK, BN, MF, ZA, LA, AC-N, EV, AS, LELMV, HGB, HvB and JA V. Subject ascertainment and recruitment were carried out by MHW, TK, BMWvB, DAK, EHMFb, BI, CLC, EL and BBAvD. Sequencing and genotyping were carried out and interpreted by WMN, HGY, LELMV, JdL and JvA. The manuscript was drafted by MHW, BN, MF, TK and AS. All authors contributed to the final version of the paper.

Funding
This work was supported by grants from the Consortium ‘Stronger on your own feel’ to TK and MHW, The Netherlands Organization for Health Research and Development (ZonMw grants 917-86-319 to BBAvD, 916-86-016 to LELMV, 917-96-346 to AS and 907-00-365 to TK), the European Union under the 7th framework program (Gencodys HEALTH-F4-2010-241995 to BBAdV, HvB, ZA, AS and TK), the Dutch Brain Foundation (to DAK and BBAvD), the Hungarian Scientific Research Fund (K-82090 to ZA), and grants from the Jérôme Lejeune foundation and from the German Federal Ministry of Education and Research (BMBF funding to the German Mental Retardation Network, MRNET to AS).

Competing interests
None.

Patient consent
Obtained.

Ethics approval
Local medical ethical committee.

Provenance and peer review
Not commissioned; externally peer reviewed.

Web resources
http://decipher.sanger.ac.uk; http://www.ecaruca.net

REFERENCES

New disease loci
New disease loci


